| scholarly article | Q13442814 |
| P50 | author | Jean-Pierre J Issa | Q55459879 |
| Hagop Kantarjian | Q60394812 | ||
| Srdan Verstovsek | Q64026418 | ||
| Josef T Prchal | Q88569926 | ||
| Carlos B Bueso-Ramos | Q90223571 | ||
| Elihu Estey | Q96145785 | ||
| Yasuhiro Oki | Q114427964 | ||
| P2093 | author name string | Miloslav Beran | |
| Jaroslav Jelinek | |||
| Vazganush Gharibyan | |||
| P2860 | cites work | Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients | Q28216361 |
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2 | Q28243103 | ||
| Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia | Q28250886 | ||
| JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin | Q28260976 | ||
| Jak2 is essential for signaling through a variety of cytokine receptors | Q28270987 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| Identification of an acquired JAK2 mutation in polycythemia vera | Q33947635 | ||
| The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes | Q35848032 | ||
| Polycythemia vera and other primary polycythemias | Q36051872 | ||
| Vascular and neoplastic risk in a large cohort of patients with polycythemia vera | Q40445951 | ||
| Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders | Q46513376 | ||
| Molecular Monitoring of Cerebrospinal Fluid Can Predict Clinical Relapse in Acute Lymphoblastic Leukemia With Eosinophilia | Q54777070 | ||
| Single-nucleotide polymorphism analysis by pyrosequencing | Q73775865 | ||
| Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia | Q78330683 | ||
| Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases | Q80607021 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| Philadelphia chromosome | Q1129111 | ||
| P304 | page(s) | 3370-3373 | |
| P577 | publication date | 2005-07-21 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia | |
| P478 | volume | 106 |
| Q34065882 | A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition |
| Q54611393 | A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. |
| Q98386625 | A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant JAK2 V617F and SETBP1 mutations: a case report and literature review |
| Q35613434 | A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth |
| Q36835063 | Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse |
| Q35607194 | Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status |
| Q46378754 | Absence of JAK2 V617F mutation in thalassemia intermedia patients |
| Q38884959 | Acquired Mutation of the Tyrosine Kinase JAK2V617F in Egyptian Patients with Myeloid Disorders |
| Q35000581 | Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities |
| Q41809583 | Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders |
| Q81241448 | Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia |
| Q37738462 | BCR-ABL-negative chronic myeloid leukemia |
| Q35030952 | CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. |
| Q41884224 | Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms |
| Q92354392 | Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling |
| Q36248587 | Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity |
| Q36340868 | Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models |
| Q37979958 | Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions |
| Q36876853 | Chronic myelomonocytic leukemia: Forefront of the field in 2015. |
| Q36337918 | Chronic myeloproliferative disorders: a tyrosine kinase tale. |
| Q36946576 | Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms |
| Q54357236 | Clonal dominance and clonal evolution in a patient with a "chronic myeloid neoplasm": a challenge in management. |
| Q35041677 | Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm. |
| Q55363972 | Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms. |
| Q37284926 | Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques |
| Q39918869 | Concordance of assays designed for the quantification of JAK2V617F: a multicenter study |
| Q35141810 | Convergent mechanisms of somatic mutations in polycythemia vera. |
| Q37089717 | Cooperating gene mutations in acute myeloid leukemia: a review of the literature. |
| Q34302770 | Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms |
| Q33555643 | Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory |
| Q37112871 | Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera |
| Q35790195 | Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases |
| Q34058657 | Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera |
| Q92527522 | Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation |
| Q43082882 | Diagnosis and management of chronic myelomonocytic leukemia |
| Q94503165 | Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera |
| Q35132241 | Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies |
| Q24685474 | Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth |
| Q36970205 | Erythroid and megakaryocytic transformation |
| Q21202968 | Essential thrombocythemia |
| Q64970549 | Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article. |
| Q40151319 | Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals |
| Q50466203 | Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. |
| Q54502586 | Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. |
| Q35849674 | Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model |
| Q94517420 | Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature |
| Q37639672 | Frequency of JAK2 V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan |
| Q37255024 | Genetic complexity of myeloproliferative neoplasms. |
| Q39028841 | Genome organization and the role of centromeres in evolution of the erythroleukaemia cell line HEL. |
| Q93085740 | Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019 |
| Q37993420 | Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations. |
| Q80313374 | High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis |
| Q36857941 | Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers |
| Q34612536 | Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts |
| Q37356617 | Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. |
| Q35910887 | In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele |
| Q80172893 | Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders |
| Q36445926 | Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia |
| Q61050111 | Insights into JAK2-V617F mutation in CML |
| Q41590802 | Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression |
| Q33843882 | JAK2 V617F detected in two B-cell chronic lymphocytic leukemia patients without coexisting Philadelphia chromosome-negative myeloproliferative neoplasms: A report of two cases |
| Q35790260 | JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology |
| Q58289362 | JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained |
| Q58455740 | JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients |
| Q41898628 | JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia |
| Q79412057 | JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia |
| Q54735977 | JAK2 V617F mutation is associated with 5q- syndrome in Chinese. |
| Q40330808 | JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders |
| Q35841611 | JAK2 V617F: a single mutation in the myeloproliferative group of disorders |
| Q37195699 | JAK2 and MPL mutations in myeloproliferative neoplasms |
| Q24609999 | JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis |
| Q38001733 | JAK2 inhibition for the treatment of hematologic and solid malignancies |
| Q37811430 | JAK2 inhibitors: what's the true therapeutic potential? |
| Q43150782 | JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. |
| Q38265111 | JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms |
| Q35615806 | JAK2(V617F): Prevalence in a large Chinese hospital population |
| Q80506444 | JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers |
| Q58023970 | JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia |
| Q89639659 | JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review |
| Q35849213 | JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model |
| Q80178942 | JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases |
| Q58455742 | JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? |
| Q55506567 | Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. |
| Q26991810 | Janus kinase deregulation in leukemia and lymphoma |
| Q37833893 | Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond |
| Q37189322 | Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. |
| Q39385436 | Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction |
| Q53313140 | MPLW515L mutation in acute megakaryoblastic leukaemia. |
| Q50642750 | Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation. |
| Q35582821 | Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation. |
| Q39691088 | Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine. |
| Q35877011 | Methylation of AR locus does not always reflect X chromosome inactivation state |
| Q37202615 | Minimal residual disease diagnostics in myeloid malignancies in the post transplant period |
| Q43979129 | Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations |
| Q38081267 | Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance |
| Q81600825 | Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia |
| Q38132817 | Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue |
| Q34474214 | Myeloid blastic transformation of myeloproliferative neoplasms—A review of 112 cases |
| Q54602496 | Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. |
| Q81943280 | Myeloproliferative disorders |
| Q37877727 | Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? |
| Q37869152 | New JAK2 inhibitors for myeloproliferative neoplasms |
| Q50766759 | On the origin of clones: learning from concurrent or sequential Philadelphia negative and positive myeloproliferative neoplasms. |
| Q79777413 | Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia |
| Q37327244 | Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders |
| Q43899490 | Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System |
| Q34687245 | Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection |
| Q33306326 | RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia |
| Q84782013 | Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform |
| Q54579263 | Rapid quantification of JAK2 V617F allele burden using a bead-based liquid assay with locked nucleic acid-modified oligonucleotide probes. |
| Q42741692 | Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. |
| Q34575418 | Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals |
| Q42200351 | Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation |
| Q80000894 | Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features |
| Q36919975 | Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders |
| Q45864132 | Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis |
| Q36173581 | STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice |
| Q82452904 | Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT |
| Q37686879 | Secondary Acute Myeloid Leukemia in a One-Year-Old Girl Diagnosed with JAK2-V617F Mutation Positive Myeloproliferative Neoplasm |
| Q42870221 | Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide |
| Q88287157 | Summary and Review of the Abstracts on Philadelphia-Negative Myeloproliferative Neoplasms Presented at Haematocon 2017 |
| Q92819319 | Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018 |
| Q83159477 | The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis |
| Q34612649 | The JAK2 V617F somatic mutation, mortality and cancer risk in the general population |
| Q37738433 | The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective |
| Q33383707 | The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model |
| Q34203062 | The aurora kinases in cell cycle and leukemia |
| Q53170263 | The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. |
| Q24675681 | The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers |
| Q50676394 | The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study. |
| Q38420427 | The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis |
| Q45038631 | The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods |
| Q36843673 | The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms |
| Q35528622 | The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. |
| Q38830536 | The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study |
| Q36527760 | The role of Janus kinases in haemopoiesis and haematological malignancy |
| Q34575802 | The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo |
| Q35433259 | Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies |
| Q28236628 | Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia |
| Q36658043 | Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice |
| Q39560322 | Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports |
| Q34298729 | Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells |
| Q36922485 | Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders |
| Q51746620 | Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting. |
| Q39174283 | Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples |
| Q81442307 | Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders |
| Q36835203 | Whole genome scanning as a cytogenetic tool in hematologic malignancies |
| Q34619256 | X-linked clonality testing: interpretation and limitations |
Search more.